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of shunt infections uses a disproportionate amount of hospital expenditure (71% of 
total management costs or € 57,650 per patient) when compared to shunt revision 
surgery (29% of total costs or € 6,720 per patient). Using shunt implant data from 
the UK Hospital Episode Statistics (HES), procedures and interventions database, 
we estimated the potential cost savings to the UK Health Care system in 2012-13 
was £1,461,207 if all new lumboperitoneal or ventriculoperitoneal shunt surgeries 
were performed using AISC systems. ConClusions: Current clinical evidence has 
demonstrated AISC reduce infection rates in shunted Hydrocephalus patients. The 
potential health care savings associated with reduced infection rates are significant.
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objeCtives: In recent years, fingolimod and natalizumab - though expensive - have 
brought significant improvements in second-line treatment of Multiple Sclerosis 
(MS). In Italy, fingolimod was acknowledged in 2011 the therapeutic innovation 
criterion which exempts the manufacturer from a mandatory discount of 5% on 
the ex-factory price for a three-year period. Since the innovation period is soon 
expiring and in order to assess the affordability of this therapy for the National and 
Regional Healthcare Systems (HSs), we performed a Budget Impact Analysis (BIA) 
of fingolimod in second-line treatment of MS, enclosed an ethical assessment of 
justice issues. Methods: A model in MSExcel was built to perform the BIA on five 
Regions located in the Nord, Centre and South of Italy. Interviews with regional 
stakeholders/clinicians provided information about epidemiology, market share, 
patient journey and resource consumption in the respective regions. Costs were 
calculated using regional tariffs for outpatient/inpatient health care services. The 
time horizon is three years which is the timeframe mostly requested by Healthcare 
Authorities. Results: Preliminary results conducted for Lazio and Sicily show that, 
in second line, the use of fingolimod compared to natalizumab leads to savings of 
€ 2,500 per patient in Lazio and € 2,700 in Sicily due to lower consumption of health 
care resources (different drug administration and patient management). The BIA 
shows that fingolimod can determine savings up to € 3.4 million approximately 
in Lazio and € 2.2 million in Sicily. Furthermore, if patients with frequent relapses 
in first line were early switched to second line, savings could be even higher: an 
additional € 2.0 million for Lazio and € 0.6 million for Sicily in the first year of treat-
ment. ConClusions: The present analysis shows that, despite innovation expiry, 
spending remains sustainable for fingolimod in the Italian and Regional HSs. 
Analyses on the other Regions must be performed to confirm such results.
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objeCtives: Relapsing-remitting multiple sclerosis (RRMS), the most common 
form of MS, imposes a considerable cost burden on health care systems. Glatiramer 
acetate 20mg/mL, a once-daily injectable disease modifying therapy (DMT), has 
long-term real-world efficacy (more than two million patient/years exposure) for 
the treatment of RRMS. An economic model was developed to estimate the financial 
impact on the UK health care system of switching RRMS treatments from glati-
ramer acetate to emerging oral (teriflunomide and dimethyl fumarate) and infused 
(alemtuzumab) DMTs over five years. Methods: The eligible patient population 
in the model was estimated based on RRMS incidence rates, and the proportion 
of people receiving glatiramer acetate in the UK in 2013 (based on market share 
data). Medication costs were derived from British National Formulary list prices, 
while treatment administration, initiation and monitoring costs were calculated 
from UK health care unit and hospital tariff codes taking account of requirements 
specified in Summary of Product Characteristics documentation. Results: The 
model estimated that 5,900 people with RRMS were receiving glatiramer acetate in 
the UK in 2013, corresponding to 17.8% of those currently receiving DMTs. Assuming 
progressive switching within the eligible RRMS population from glatiramer acetate 
to teriflunomide (from 1–6% in year one to five), dimethyl fumarate (1–6%) and 
alemtuzumab (1–3%), additional spending of £17.0 million, £65.3 million and £147.6 
million over one, three and five years, respectively, was incurred. This was primarily 
driven by higher acquisition costs compared with glatiramer acetate. Administration 
requirements associated with alemtuzumab, and the initiation and monitoring 
requirements of the oral DMTs also contributed to additional costs. ConClusions: 
No data exist supporting the clinical superiority – and therefore associated eco-
nomic benefit – of the emerging DMTs over glatiramer acetate; switching patients 
from glatiramer acetate to new therapies may be associated with substantial costs 
for the UK health care system.
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objeCtives: In Portugal there are about 2,694 patients treated with interferon 
beta (IFNB) and it is estimated that 30.4% are poor responders. Fingolimod treat-
ment costs are an obstacle to treatment escalation, despite the fact that early 
initiation of fingolimod may impact favorably on long-term clinical outcomes. 
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objeCtives: To summarize rates of prevalence, incidence and types of multiple 
sclerosis (MS) in Latin America. Methods: We searched Medline, Embase, Scielo 
and LILACS using key words “multiple sclerosis” and “esclerosis múltiple”, plus 
“Latin America” and all country names. Accepted were full articles or abstracts 
reporting original research in any language at any time, with MS diagnosed using 
any acceptable criteria. Clinically isolated syndrome was excluded. Results: 1482 
articles were identified and 203 reviewed in full; 88 were rejected and 115 were 
analyzed (38 prevalence, 3 incidence, 2 both, 72 clinical epidemiology), including 
68 (59%) full text and 47 (41%) abstracts. Studies originated in 14 countries, mostly 
larger, more affluent nations (47% Brazil, 15% Argentina, 8% Mexico). Prevalence 
studies examined 19,357 MS cases from 1968-2012; rates ranged from 0 in a group 
of Mexican natives to 52/100,000 in Puerto Rico, with a mean of 13.9/100,000. This 
range would be classified as low to medium, with 83,000 (CI95%: 62,000-104,000) 
prevalent cases in Latin America. Incidences ranged from 0.15/100,000 person-
years in Panama to 1.76 in Argentina (median= 1.32, mean= 1.35), or 7,887-8,365 new 
cases/year in Latin America. Authors noted increasing prevalence and incidence 
rates over time. Clinical epidemiology MS data were obtained from 94 studies; 66% 
used Poser criteria, 48% McDonald (various versions), and 14% other, from 19,893 
patients (72% females). The average age at assessment was 38.2 and 32.2 at disease 
onset with average EDSS of 3.1. The relapsing-remitting form was most prevalent 
(74% of cases), followed by secondary progressive (12%) and primary progressive 
(10%). ConClusions: MS prevalence and incidence rates vary widely in Latin 
America in a low to medium range, but are increasing as reported in the reviewed 
studies. Information is scant with many gaps. More research is needed to provide 
a basis for decision making and budget allocation.
PND16
eNtacaPoNe DID Not INcRease PRostate caNceR RIsk oR moRtalIty  
IN PatIeNts wIth PaRkINsoN’s DIsease
Korhonen P.1, Kuoppamäki M.2, Prami T.1, Hoti F.1, Christopher S.1, Ellmén J.2, Aho V.2, 
Vahteristo M.2, Pukkala E.3, Haukka J.1
1EPID Research, Espoo, Finland, 2Orion Corporation, Espoo, Finland, 3Finnish Cancer Registry, 
Helsinki, Finland
objeCtives: The association between Parkinson’s disease (PD) and prostate can-
cer (PCA) is under discussion. We investigated whether exposure to entacapone 
increases risk of PCA by comparing PCA incidence and mortality rates in PD patients 
treated with levodopa and dopa decarboxylase inhibitors (DDCIs) with or without 
entacapone as an adjuvant. Methods: This was a retrospective population-based 
register cohort study in Finland. Male PD patients exposed to levodopa/DDCI with 
entacapone and patients on levodopa/DDCI without entacapone between 1998 and 
2009 were identified from the Finnish Prescription Register. Concomitant treat-
ment with dopamine agonists (DA) and monoamine oxidase B (MAO-B) inhibitors 
was allowed. PCA cases and PCA deaths were identified from the Finnish Cancer 
Register and from the Cause of Death Register. PCA Incidence and mortality of 
PCA were modeled by Cox’s proportional hazards model with adjustments for rel-
evant baseline and time-dependent variables. The robustness of the findings for 
PCA incidence was evaluated in sensitivity analyses with alternative definitions 
for exposure and by using a nested case-control study setting with 4-5 individually 
matched controls randomly selected for each incident prostate cancer case within 
the cohort. Results: The study cohort consisted of 11 396 male patients. During a 
mean follow-up time of 4.7 years 359 PCA cases and 89 PCA deaths were observed. 
Entacapone use with levodopa/DDCI did not increase the risk of PCA incidence 
[hazard ratio (HR) 1.05, 95% CI 0.76-1.44] or PCA mortality (HR 0.93,95% CI 0.43-1.98) 
when compared to levodopa/DDCI without entacapone. For cumulative entacapone 
use (exposure > 360 days vs. never use) the HR was 0.82 (95% CI 0.56-1.18) for PCA 
incidence and 1.27 (95% CI 0.60-2.72) for PCA mortality. The results for PCA incidence 
were found robust in the sensitivity analyses. ConClusions: No increased risk in 
PCA incidence or PCA mortality was seen in relation to entacapone use.
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bACkgRound: Shunt infections are one of the most serious and costly compli-
cations associated with shunt therapy. They can have long-term consequences 
to the patient and impose significant burden on the family and health care sys-
tem. objeCtives: To investigate the clinical and economic value of AISC in the 
treatment of Hydrocephalus. Methods: A search of the Embase, PubMed, and NHS 
EED electronic databases was conducted to identify studies evaluating the effective-
ness, efficacy and economic aspects of AISC’s in patients with Hydrocephalus. No 
language restrictions were applied. Results: Twenty-three clinical and 9 economic 
studies were included for review. The majority of published studies using AISC 
in the treatment of hydrocephalus demonstrated a statistically significant reduc-
tion in shunt-associated infections when AISC vs. standard shunt (SS) catheters 
were used. One meta-analysis of 14 studies that compared patients implanted with 
AISC to SS catheters showed AISC to be protective against shunt infection in both 
paediatric and adult Hydrocephalus patients. The pooled infection rate decreased 
from 7.0% in the SS catheter group to 3.5% in the AISC group. Economic studies 
conducted globally reported significant cost savings associated with using AISC. 
One study in paediatric Hydrocephalus patients found that ongoing management 
